Silence Therapeutics Plc American Depository Share (SLN) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 81.3% versus a gain of 5.3%. Over five years, ZVRA leads with a +16.6% price change compared with -56.4% for SLN. Zevra Therapeutics is the larger company by market cap ($676.4 million vs $612.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLN | ZVRA |
|---|---|---|
| Share price | $9.86 | $11.39 |
| Market cap | $612.84M | $676.38M |
| 1-day change | +3.57% | +3.55% |
| YTD return | +56.58% | +27.12% |
| 1-year return | +81.33% | +5.27% |
| 5-year return | -56.37% | +16.58% |
| P/E ratio (TTM) | — | 12.38 |
| Forward P/E | — | 10.58 |
| EPS (TTM) | $-1.29 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.58 | $15.04 |
| 52-week low | $4.19 | $8.01 |
| Distance from 52-week high | -43.90% | -24.24% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +234.69% | +119.49% |
| Average volume | 1.14M | 1.11M |
| Shares outstanding | 62.15M | 59.38M |
| Employees | 88 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed ZVRA by 76.1 percentage points over the past year.
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
SLN vs ZVRA FAQ
Which is bigger, Silence Therapeutics Plc American Depository Share or Zevra Therapeutics?
Zevra Therapeutics (ZVRA) is larger, with a market capitalization of $676.38M compared with $612.84M for Silence Therapeutics Plc American Depository Share (SLN).
Which stock has performed better over the past year, SLN or ZVRA?
SLN returned +81.33% over the past 12 months, compared with +5.27% for ZVRA (price return, excluding dividends). Past performance does not predict future results.
Are Silence Therapeutics Plc American Depository Share and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.